Meeting
2014 ASCO Annual Meeting
Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval.
Authors
Denis Leonardo Fontes Jardim
University of Campinas, Campinas, Brazil
Denis Leonardo Fontes Jardim , Maria Clemence Schwaederle , J. Jack Lee , David S. Hong , Alexander M. Eggermont , Richard L. Schilsky , John Mendelsohn , Vladimir Lazar , Razelle Kurzrock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11047)
DOI
10.1200/jco.2014.32.15_suppl.11047
Abstract #
11047
Poster Bd #
329
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.
First Author: J. Carlos Tapia
Poster
2020 ASCO Virtual Scientific Program
Reassessing the net health benefit (NHB) of FDA approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology Value Framework (ASCO-VF).
First Author: Seanthel Delos Santos
Poster
2023 ASCO Breakthrough
Disparities in African-American patient enrollment in pivotal phase 3 immunotherapy trials that led to FDA drug approval in patients with non-small cell lung cancer.
First Author: Chimezie Ubbaonu
Poster
2023 ASCO Annual Meeting
The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.
First Author: Ademola Samuel Ojo